BERKELEY, Calif., Jan. 9, 2012—ExThera Medical Corporation, Inc., announced today that it has appointed three distinguished medical scientists to the firm’s first Medical Advisory Board.
The ExThera Medical Advisory Board now includes:
- James Anderson, M.D., Ph.D., Professor of Pathology, Macromolecular Science and Biomedical Engineering at Case Western Reserve University (Cleveland), who is also a consultant to the National Institutes of Health’s Artificial Heart Program, the FDA, and the International Standards Organization (ISO 10993). Dr. Anderson is Co-Founder of the Society of Biomaterials and Editor in Chief, Journal of Biomedical Materials Research, and a member of the Institute of Medicine (IOM) of the National Academies of Science; and
- George W. Bo-Linn, M.D., former Senior Vice President and Chief Medical Officer of Catholic Healthcare West, (San Francisco) and current Chief Program Officer for the San Francisco Bay Area Program for Healthcare at the Gordon and Betty Moore Foundation. Dr. Bo-Linn served previous appointments as Chief Medical Officer with Unity Health System (St. Louis), University of Texas Medical School at Dallas, Baylor University Medical Center and Johns Hopkins Hospital; and
- Steven P. LaRosa, M.D., Associate Professor of Medicine at Texas A&M Health Science Center College of Medicine, Director of the Division of Infectious Disease at Scott & White Healthcare (Temple, Tex.), and Lead Clinical Research Physician for the Phase III trial of recombinant human-activated protein C (rhAPC, Xigris™) in severe sepsis. Dr. LaRosa served previous appointments with Cleveland Clinic Foundation and Warren Alpert Medical School of Brown University.
“Given that ExThera is initiating its clinical development program, we are extremely excited to be working with three of the world’s leading medical scientists,” said Robert S. Ward, President and Chief Executive Officer. “Our mission to develop the world’s only broad-spectrum device-based therapy for the treatment of bacteremia and sepsis will require the talent and determination of experienced medical professionals who understand the multi-factorial nature of this disease group. We are progressing in our development of protocols for our European clinical trials scheduled to begin later this year and are very fortunate to have the clinical guidance of Dr. Anderson, Dr. Bo-Linn and Dr. LaRosa. We are certain that their contributions as individuals, and as a group, will be extraordinary.”
Founded in 2007 as a joint venture with ExThera AB, a spin-out of the Karolinska Institute to commercialize a technology that captures and removes from human circulation pathogens, toxins, virulence factors, and cytokines, ExThera Medical is a privately held development-stage company.
